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A B S T R A C T
Background
Tinnitus is the perception of sound or noise in the absence of an external or internal acoustic stimulation. It is a common and potentially
distressing symptom for which no adequate therapy exists.
Objectives
To assess the effectiveness of anticonvulsants in patients with chronic tinnitus.
Search methods
We searched the Cochrane Ear, Nose and Throat Disorders Group Specialised Register, CENTRAL (2010, Issue 2), MEDLINE,
EMBASE, bibliographies and additional sources for published and unpublished trials. The date of the most recent search was 26 May
2010.
Selection criteria
We selected randomised controlled trials in patients with chronic tinnitus comparing orally administered anticonvulsants with placebo.
The primary outcome was improvement in tinnitus measured with validated questionnaires. Secondary outcomes were improvement in
tinnitus measured with self-assessment scores, improvement in global well-being or accompanying symptoms, and adverse drug effects.
Data collection and analysis
Three authors assessed risk of bias and extracted data independently.
Main results
Seven trials (453 patients) were included in this review. These studies investigated four different anticonvulsants: gabapentin, car-
bamazepine, lamotrigine and flunarizine. The risk of bias of most studies was ’high’ or ’unclear’. Three studies included a validated
questionnaire (primary outcome). None of them showed a significant positive effect of anticonvulsants. One study showed a significant
negative effect of gabapentin compared to placebo with an increase in Tinnitus Questionnaire (TQ) score of 18.4 points (standardised
mean difference (SMD) 0.82, 95% confidence interval (CI) 0.07 to 1.58). A second study showed a positive, non-significant effect of
gabapentin with a difference compared to placebo of 2.4 points on the Tinnitus Handicap Inventory (THI) (SMD -0.11, 95% CI -
0.48 to 0.25). When the data from these two studies are pooled no effect of gabapentin is found (SMD 0.07, 95% CI -0.26 to 0.40).
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A third study reported no differences on the THI after treatment with gabapentin compared to placebo (exact numbers could not be
extracted from the article).
A meta-analysis of ’any positive effect’ (yes versus no) based on a self-assessment score (secondary outcome) showed a small favourable
effect of anticonvulsants (RD 14%, 95% CI 6% to 22%). A meta-analysis of ’near or total eradication of tinnitus annoyance’ showed
no effect of anticonvulsants (risk difference (RD) 4%, 95% CI -2% to 11%). Side effects of the anticonvulsants used were experienced
by 18% of patients.
Authors’ conclusions
Current evidence regarding the effectiveness of anticonvulsants in patients with tinnitus has significant risk of bias. There is no evidence
from studies performed so far to show that anticonvulsants have a large positive effect in the treatment of tinnitus but a small effect (of
doubtful clinical significance) has been demonstrated.
P L A I N L A N G U A G E S U M M A R Y
Anticonvulsants for tinnitus
Tinnitus is the perception of sound or noise in the absence of external acoustic stimulation. It is a common and potentially distressing
symptom for which no adequate therapy exists. The pathophysiology of tinnitus has been compared to phantom limb pain therefore
anticonvulsant drugs have been proposed as a possible therapy.
This review includes seven studies (six low-quality and one high-quality) of four different anticonvulsants (gabapentin, carbamazepine,
flunarizine and lamotrigine). We found that anticonvulsants do not have a beneficial effect in the treatment of tinnitus. Side effects of
the anticonvulsants used were experienced by 18% of patients.
B A C K G R O U N D
Background
This is one of a number of tinnitus reviews produced by the
Cochrane Ear, Nose & Throat Disorders Group. The following
paragraphs (’Description of the condition’) are partially based on
earlier work in the following reviews and reproduced with per-
mission: Baldo 2006; Bennett 2007; Hilton 2004; Hobson 2010;
Phillips 2010.
Description of the condition
Tinnitus is a phantom auditory perception of meaningless sound
in the absence of an external or internal acoustic stimulation.
While for the patient this perception of noise is very real, it can
be considered a phantom, or false, perception because there is no
corresponding external sound. For the patient it may be trivial or
it may be a debilitating condition (Luxon 1993). The characteris-
tics of the perceived sound (description, number, frequency, onset,
presence and location of the sound) can vary enormously between
patients. For example, patients may hear a single sound or multi-
ple sounds, it may be perceived in one ear, both ears, within the
head or outside the body and the symptom may be continuous or
intermittent.
It is important to distinguish between clinically significant and
non-significant tinnitus (Davis 2000) and several different classi-
fications have been proposed (Dauman 1992; McCombe 2001;
Stephens 1991). Severe tinnitus, defined as tinnitus interfering
with the normal way of life, is reported in up to 5% of tinnitus
patients (Coles 1984; Davis 2000; Nondahl 2002). It is usually
associated with other symptoms, such as hyperacusis and many
of these patients also suffer from affective disorders and sleeping
problems (Crummer 2004; Henry 2005; Jastreboff 2003; Moller
2003).
Differentiation between tinnitus and somatosounds (perceptions
of sound caused by an internal acoustic source, due to either a
vascular abnormality or a muscular or anatomical cause such as
sound generated by blood flow in or around the ear or unusual
activity of middle ear muscles within the middle ear) is important
because they have different pathophysiologies and therefore differ-
ent therapeutic approaches. Somatosounds are usually objective;
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they can be detected by an examiner, either unaided or using a
listening aid such as a stethoscope or microphone in the ear canal.
Somatasounds are much less common than tinnitus. Tinnitus is
by definition always subjective, meaning that it cannot be heard
by anyone other than the patient, while for the patient this per-
ception of noise is real.
Aetiology
The most common causes of tinnitus are otological disorders,
most frequently noise and age-induced sensorineural hearing loss,
or other types of sensorineural hearing loss. Conductive hearing
loss can also cause tinnitus, sometimes transient. Almost any form
of disorder involving the outer, middle or inner ear or the audi-
tory nerve may be associated with tinnitus (Brummet 1980; Shea
1981). However, it is possible to have severe tinnitus with no ev-
idence of any aural pathology. Presumably in these cases there is
a moderate degree of aural pathology, but not evident enough to
be able to diagnose with current diagnostic methods (audiometry
only screens a portion of the auditory function). Non-otological
causes of tinnitus have also been described, but the causal relation-
ship is less understood. Conversely, tinnitus can even exist with-
out a peripheral auditory system: when the cochlear nerve is sev-
ered patients retain their tinnitus (Baguley 1992). This suggests
the fundamental importance of the central auditory pathways in
the development or maintenance of the symptom, irrespective of
trigger.
Pathophysiology
Over 50 years ago, Heller and Bergman demonstrated that if ’nor-
mal’ people (with no known cochlear disease) were placed in a
quiet enough environment, the vast majority of them would ex-
perience sounds inside their head. They concluded that tinnitus-
like activity is a natural phenomenon perceived by many in a quiet
enough environment (Heller 1953).
Despite the high prevalence and morbidity of tinnitus, its patho-
physiology is poorly understood. It is probable that different pro-
cesses are involved in the generation of tinnitus; for example, when
it is transient or chronic or when it is caused by conductive or
sensorineural hearing loss. Possible theories on the pathophysiol-
ogy focus on dysfunction of hair cells, the auditory nerve or cen-
tral auditory system. In the ’neurophysiological model’ of tinnitus
(Jastreboff 1990; Jastreboff 2004) it is proposed that tinnitus re-
sults from the abnormal processing of a signal generated in the au-
ditory system. This abnormal processing occurs before the signal
is perceived centrally. This may result in ’feedback’, whereby the
annoyance created by the tinnitus causes the individual to focus
increasingly on the noise, which in turn exacerbates the annoy-
ance and so a ’vicious cycle’ develops. In this model tinnitus could
therefore result from continuous firing of cochlear fibres to the
brain, from hyperactivity of cochlear hair cells or from permanent
damage to these cells being translated neuronally into a ’phantom’
sound-like signal that the brain ’believes’ it is hearing.
It is commonly thought that chronic tinnitus (caused by sen-
sorineural hearing loss) is generated in the brain as a result of
functional reorganisation of the primary auditory cortex, follow-
ing damage to the peripheral auditory system (Eggermont 2004).
This functional reorganisation would cause the tonotopic maps in
the central auditory cortex to alter. This altering of maps has in-
deed been shown in humans with tinnitus (Muhlnickel 1998). On
the neuronal level, it is thought that this functional reorganisation
causes an increased spontaneous firing rate of neurons in the au-
ditory cortex and auditory brainstem, and an increased synchro-
nisation of spontaneous activity of cortical neurons (Eggermont
2004; Norena 2003; Ochi 1997). This increase in firing rate and
synchronisationwould lead to hyperactivity in the central auditory
system. This resulting hyperactivity has been shown in functional
magnetic resonance imaging (fMRI) research in tinnitus patients
(Giraud 1999; Lockwood 1998; Melcher 2000). The mechanism
underlying this increase in spontaneous firing rate and synchro-
nisation is thought to be reduced inhibition, which is the conse-
quence of the decreased output from damaged cochlear regions
(Eggermont 2004; Salvi 2000).
The relationship between the symptom of tinnitus and the activ-
ity of the prefrontal cortex and limbic system has been empha-
sised. The limbic system mediates emotions. It can be of great
importance in understanding why the sensation of tinnitus is in
many cases so distressing for the patient. It also suggests why, when
symptoms are severe, tinnitus can be associated with major depres-
sion, anxiety and other psychosomatic and/or psychological dis-
turbances, leading to a progressive deterioration of quality of life
(Lockwood 1999; Sullivan 1989; Sullivan 1992; Sullivan 1993).
Prevalence
Epidemiological data reports are few. Reports show that tinni-
tus is common, affecting approximately 7% to 19% of the adult
population (Chung 1984; Coles 1984; Davis 1989; Davis 2000;
Henry 2005; Nondahl 2002). This substantial variance might be
explained by the different definitions and criteria of tinnitus that
were used and the different populations that were investigated.
The largest single study was undertaken in the UK by the Medi-
cal Research Council Institute of Hearing Research and was pub-
lished in 2000 (Davis 2000). This longitudinal study of hearing
questioned 48,313 people; 10.1% described tinnitus arising spon-
taneously and lasting for five or more minutes at a time and 5%
described it as moderately or severely annoying. However, only
0.5% reported tinnitus having a severe effect on their life. This is
another of the paradoxes of tinnitus: the symptom is very common
but the majority of people who experience it are not particularly
concerned by it. These figures from the UK are broadly consistent
with data collected by the American Tinnitus Association (ATA)
which suggests that tinnitusmay be experienced by around 50mil-
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lion Americans, or 17% of the US population (ATA 2004). Data
also exist for Japan, Europe and Australia (Sindhusake 2003), and
estimates suggest that tinnitus affects a similar percentage of these
populations, with 1% to 2% experiencing debilitating tinnitus
(Seidman 1998). Tinnitus can occur at any age, but the prevalence
increases with advancing age (peak prevalence between 40 and
70 years) (Baguley 1999; Crummer 2004; Davis 2000; Hegarthy
2000;Henry 2005; Schleuning 1991). TheOregonTinnitus Data
Archive (Oregon 1995) contains data on the characteristics of tin-
nitus drawn from a sample of 1630 tinnitus patients. The age
groups with the greater prevalence are those between 40 and 49
years (23.9%) and between 50 and 59 years (25.6%).
Diagnosis
Firstly a patient with tinnitus may undergo a basic clinical assess-
ment. This will include the relevant otological, general and family
history, and an examination focusing on the ears, teeth and neck
and scalp musculature. Referral to a specialist is likely to involve
a variety of other investigations including audiological tests and
radiology. Persistent, unilateral tinnitus may be due to a specific
disorder of the auditory pathway and imaging of the cerebello-
pontine angle is important to exclude, for example, a vestibular
schwannoma (acoustic neuroma) - a rare benign tumour of the
cochleo-vestibular nerve. Other lesions, such as glomus tumours,
meningiomas, adenomas, vascular lesions or neuro-vascular con-
flicts may also be detected by imaging (Marx 1999; Weissman
2000).
Treatment
At present no specific therapy for tinnitus is acknowledged to be
satisfactory in all patients. Many patients who complain of tinni-
tus, and also have a significant hearing impairment, may benefit
from a hearing aid (Del Bo 2007). Not only will this help their
hearing disability but the severity of their tinnitus may be reduced
by masking it through the amplification of ambient sounds. Tin-
nitus masking can also be achieved with devices which produce
a sound that can reduce or eliminate the perception of tinnitus
(Hobson 2010).
The role of pharmacotherapy in the treatment of tinnitus is still in-
conclusive. A wide range of drugs have been proposed for the treat-
ment of tinnitus symptoms since it was shown that intravenous lig-
nocaine may be effective in suppressing tinnitus in some patients
(Melding 1978). Pharmacological interventions used include cor-
tisone (Koester 2004), vasodilators, benzodiazepines, lidocaine
and spasmolytic drugs. Antidepressants are commonly prescribed
for tinnitus. However, two reviews (Baldo 2006; Robinson 2007)
have shown that there is no indication that tricyclic antidepressants
have a beneficial effect. A Cochrane Review showed that there is
no evidence that Ginkgo biloba is effective (Hilton 2004).
Psychological therapies (counselling, cognitive behavioral therapy
(CBT) and tinnitus retraining therapy (TRT)) may diminish tin-
nitus by lessening the distress caused by it or by improving quality
of life by teaching coping strategies, relaxation techniques and dis-
traction skills (Andersson 1999; Martinez 2010; Phillips 2010). A
Cochrane Review has shown that CBT can have an effect on the
qualitative aspects of tinnitus and can improve patients’ ability to
manage the condition (Martinez 2010).
Other options for themanagement of patients with tinnitus which
have been evaluated, include music therapy (Argstatter 2008), tra-
ditional Chinese medicine, including acupuncture (Li 2009) and
hyperbaric oxygen therapy (HBOT). Hyperbaric oxygen therapy
(HBOT) can improve oxygen supply to the inner ear which, it
is suggested, may result in an improvement in tinnitus, however
a Cochrane Review found insufficient evidence to support this
(Bennett 2007).
Different treatment modalities, working on the assumption that
tinnitus is related to central auditory hyperactivity, are being eval-
uated, including transcranial magnetic stimulation (Meng 2009)
and extradural electrical stimulation of the auditory cortex (De
Ridder 2007).
Anticonvulsants
Anticonvulsants form an important group of drugs used in the
treatment of tinnitus, again because of the assumption that tinnitus
is related to central auditory hyperactivity. Several different reviews
and non-randomised controlled trials have been published which
mention anticonvulsants (Dobie 1999; Goodey 1981; Melding
1979; Shea1978;Waddell 2005). Anticonvulsantsmight diminish
this hyperactivity and treat tinnitus in three ways:
1. they may enhance inhibition in the central auditory system
by augmenting the action of gamma-aminobutyric acid (GABA),
an inhibitory neurotransmitter;
2. they may lower the excitation level in the central auditory
system by lessening glutamate transmission, an excitatory
neurotransmitter;
3. they may halt the depolarisation of cells, and thus central
activation, by blocking voltage-dependent sodium channels.
The effectiveness of anticonvulsants in tinnitus patients is, how-
ever, not yet clear. A comprehensive systematic review and meta-
analysis of randomised controlled trials evaluating the effectiveness
of anticonvulsants in patients with chronic tinnitus is therefore
warranted.
O B J E C T I V E S
To assess the effectiveness of anticonvulsants in patients with
chronic tinnitus.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We considered all randomised controlled trials and cross-over tri-
als (if data could be extracted before the cross-over) in which an-
ticonvulsants were compared with placebo, for inclusion in this
review. Desirable time points of outcome assessment were four
and eight weeks. We excluded single-dose studies.
Types of participants
Patients with chronic tinnitus.
We excluded studies on patients with somatosounds (carotid
pathology, arteriovenous malformations, high cardiac output, hy-
pertension, aortic murmurs, vascular tumours, atherosclerosis of
the subclavian artery, persistent stapedial artery, turbulent stream
in the jugular vein, pseudotumour cerebri or myoclonus of the
muscles in the palate or within the ear) and patients with auditory
hallucinations. Somatosounds were differentiated on the basis of
brain imaging or on characteristic features in the patient’s history.
Types of interventions
We included studies using orally administered anticonvulsants
(without restrictions regarding type of anticonvulsant, dose or fre-
quency) versus placebo.
Types of outcome measures
Primary outcome
• Improvement in tinnitus-specific health-related quality of
life measured with validated questionnaires, such as the Tinnitus
Questionnaire (TQ), Tinnitus Handicap Inventory (THI),
Tinnitus Handicap Questionnaire (THQ) or Tinnitus
Experience Questionnaire (TEQ).
Secondary outcomes
• Improvement in self-assessment of tinnitus severity
measured with self-assessment scores.
• Improvement in accompanying symptoms, such as
depression, anxiety or sleeping problems measured with
validated questionnaires such as the Profile of Mood States, Beck
Depression Scale, State-Trait Anxiety Inventory or Brief
Symptom Inventory.
• Adverse drug effects.
Search methods for identification of studies
We conducted systematic searches for randomised controlled trials
on the effectiveness of anticonvulsants in patients with tinnitus.
There were no language, publication year or publication status
restrictions. The date of the last search was 26 May 2010.
Electronic searches
We searched the following databases from their inception: the
Cochrane Ear, Nose and Throat Disorders Group Trials Regis-
ter; the Cochrane Central Register of Controlled Trials (CEN-
TRAL) (The Cochrane Library 2010, Issue 2); PubMed (1950 on-
wards); EMBASE (1974 onwards); CINAHL (1982 onwards);
PsycINFO; LILACS; KoreaMed; IndMed; PakMediNet; CNKI;
MEMR (Index Medicus for WHO Eastern Mediterranean Re-
gion); IMSEAR (Index Medicus for WHO South-East Asia Re-
gion); Hellis Metasearch; J-East (Science Links Japan); UKCRN
(the UK Clinical Research Network Portfolio Database); IC-
TRP (the World Health Organization International Clinical
Trials Registry Platform); ClinicalStudyResults.org; mRCT (the
metaRegister of Controlled Trials) and Google.
Search strategies
Subject strategies for databases were modelled on the search strat-
egy designed for CENTRAL (see Appendix 1). Where appropri-
ate, we combined subject strategies with adaptations of the highly
sensitive search strategy designed by the Cochrane Collaboration
for identifying randomised controlled trials and controlled clinical
trials (as described in theCochraneHandbook for Systematic Reviews
of Interventions Version 5.0.1, Box 6.4.b. (Handbook 2008)).
Searching other resources
We checked the reference lists of identified publications for addi-
tional trials. We searched PubMed, TRIPdatabase, NLH ENT &
Audiology Specialist Library and Google to retrieve existing sys-
tematic reviews possibly relevant to this systematic review, so that
we could scan their reference lists for additional trials. We sought
abstracts from conference proceedings via the Cochrane Ear, Nose
and Throat Disorders Group Trials Register and CENTRAL.
Data collection and analysis
We conducted the review according to the recommendations of
theCochraneHandbook for Systematic Reviews of Interventions 5.0.1
(Handbook 2008).
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Selection of studies
Two review authors (CELH and SPR) scanned the retrieved ab-
stracts to identify relevant randomised controlled trials. The same
two authors reviewed the full texts of these articles.We assessed the
eligibility of the trials independently. We resolved any differences
in opinion by discussion.
Data extraction and management
Three authors (CELH, SPR and MMR) independently collected
and extracted data. Disagreement was resolved by discussion. We
extracted the following data from each study: number of included
patients, inclusion and exclusion criteria, intervention and placebo
information, trial duration, primary and secondary outcomes, fol-
low up and adverse events. We contacted the original authors for
clarification and further data if trial reports were unclear. Where
necessary we arranged translations of papers.
Assessment of risk of bias in included studies
We assessed the quality of the included studies using the Cochrane
Collaboration’s tool for assessing risk of bias (’Risk of bias’ table,
Cochrane Handbook for Systematic Reviews of Interventions, chap-
ter 8 (Handbook 2008, version 5.0.1). We addressed six specific
domains, i.e. sequence generation, allocation concealment, blind-
ing, incomplete outcome data, selective outcome reporting and
’other biases’. By answering pre-specified questions we judged the
risk of bias for each domain as ’yes’ (low risk of bias), ’no’ (high
risk of bias) or ’unclear’. We resolved disagreement by discussion
(CELH, SPR and MMR). We planned to assess publication bias
with a scatter plot (funnel plot) of the log rate ratios (x-axis) versus
precision defined as 1/standard error (y-axis) (Handbook 2008).
Assessment of heterogeneity
If heterogeneity was low (I2 < 25%) we calculated the sum-
mary weighted risk differences and 95% confidence intervals (CIs)
(random-effects model) by the Mantel-Haenszel method, which
weighs studies by the number of events in the control group, using
the Cochrane statistical package in Review Manager (RevMan)
(version 5.1) (RevMan 2011).
Data synthesis
We used RevMan 5.1 to carry out the meta-analyses for compara-
ble trials and outcomes. For continuous outcomes (questionnaire
scores) we calculated standardised mean differences (SMD) and
their corresponding 95% confidence intervals (CI). We calculated
standardised mean differences by dividing the difference between
means by the standard deviation. For dichotomous outcomes, we
measured the estimates of effect as risk differences (RD) with their
corresponding 95% confidence intervals. We calculated risk dif-
ferences using: (proportion of patients with improvement in in-
tervention group) - (proportion of patients with improvement in
placebo group). Furthermore, we also planned to perform sensitiv-
ity analyses excluding the studies with the lowest methodological
quality, according to the Cochrane Collaboration’s risk of bias as-
sessment, to establish whether this factor influences the final out-
come. We also intended to perform subgroup analyses for cause of
tinnitus, duration of tinnitus, patient age, type of anticonvulsant
used and outcome measures used. Ultimately it was not possible
to perform sensitivity and subgroup analysis, mainly because of
lack of data concerning these factors in the original articles.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
We found 96 studies through the combined searches. First, we
sifted the articles by title/abstract, leaving 15 articles to read in full
text. We excluded eight publications from the review: five articles
(Bauer 2006; Guth 1990; Marks 1981; Menkes 1998; Shulman
2008) did not fit the criteria for this review (no anticonvulsant,
non-RCT, comments) and three articles (Castagno 1989; Halmos
1982; Viada 1981) were not available through the databases that
we used or through the internet. We identified no additional trials
by checking the bibliographies of the selected trials.
Included studies
We included seven trials (453 patients) that looked at the effec-
tiveness of anticonvulsants in patients with tinnitus in this review
(Bakhshaee 2007;Donaldson 1981;Hulshof 1985;Hulshof 1986;
Piccirillo 2007; Simpson 1999; Witsell 2006).
Design
Five trials had a randomised controlled trial design (Bakhshaee
2007; Hulshof 1985; Hulshof 1986; Piccirillo 2007; Witsell
2006). The other two studies were cross-over trials (Donaldson
1981; Simpson 1999).
Sample size
The average sample size was 62 patients (range 9 to 135 patients).
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Settings
Some studies did not describe their settings (Bakhshaee 2007;
Hulshof 1985; Piccirillo 2007). The other studies described their
settings only broadly. Two studies were performed in a tinnitus
clinic population (Donaldson 1981; Simpson 1999). One study
included patients from a regular otorhinolaryngology practice and
also through public advertisement (Witsell 2006). Another study
mentioned only that outpatients were included (Hulshof 1986).
Participants
Participant characteristics and inclusion and exclusion criteriawere
not reported in great detail in most studies. Four studies men-
tioned the age groups that were included, ranging from 18 to 81
years (Bakhshaee 2007; Piccirillo 2007; Simpson 1999; Witsell
2006). Four studies gave information on the duration of the
tinnitus. Three studies included patients with tinnitus present
at the same level at enrolment for more than the preceding six
months (Bakhshaee 2007; Piccirillo 2007; Simpson 1999) and one
study included patients with tinnitus for more than three months
(Witsell 2006). One study described the character of the tinni-
tus, which needed to be continuous and non-pulsatile (Bakhshaee
2007). Five studies applied restrictions on the degree of tinni-
tus. Three studies used a broad description as “annoying tinni-
tus” (Hulshof 1985; Hulshof 1986) or “sufficient severity to dis-
rupt daily activities” (Piccirillo 2007). Two studies used a minimal
score on a questionnaire or visual analogue scale; > 38 on the THI
(Piccirillo 2007), > 30 on the TQ (Bakhshaee 2007) or > 5 on a
visual analogue scale (VAS) of 0 to 10 (Simpson 1999).
The exclusion criteria most often mentioned were related to the
anticonvulsants used (Bakhshaee 2007; Piccirillo 2007; Simpson
1999; Witsell 2006). Two studies restricted patients on their hear-
ing level. One included only patients with a sensorineural hearing
loss but patients with deafness were excluded (a definition for deaf-
ness was not given) (Donaldson 1981). The other study did not
include patients with Ménière’s disease, conductive hearing loss,
sensorineural hearing loss of “well-knownaetiology” , ormore than
moderately severe loss (> 50 (no units given)) in at least one fre-
quency (Bakhshaee 2007). The exclusion criterion “sensorineural
hearing loss of well-known etiology” includes noise-induced hear-
ing loss, but is not explained any further. Three studies excluded
participants with cognitive disorders or impairment (Bakhshaee
2007; Piccirillo 2007; Witsell 2006).
Baseline patient characteristics were often not reported, precluding
any judgements about the comparability of the patient groups
both within and between trials.
Interventions
These studies investigated four different anticonvulsants.
Gabapentin was the drug of investigation in three trials in dif-
ferent dosages and duration (four weeks 900 mg per day; four
weeks 1800 mg per day; eight weeks 3600 mg per day) (Bakhshaee
2007; Piccirillo 2007; Witsell 2006). Two studies looked at car-
bamazepine in different dosages and durations (eight weeks 200
mg; four weeks 450 mg) (Donaldson 1981; Hulshof 1985). Lam-
otrigine and flunarizine were both studied in one trial (Hulshof
1986; Simpson 1999). All studies were placebo-controlled.
None of the studies included another form of treatment during
the study period (such as counselling, for example). All studies had
one or more evaluation time points. None of the studies described
in detail how or by whom the evaluation was performed and if
there was any form of interaction between the clinician and the
patients during the study.
Outcomes
Three studies used a validated questionnaire as outcome measure-
ment (our primary outcome measure); the Tinnitus Handicap
Inventory (THI) was used in two trials (Piccirillo 2007; Witsell
2006) and the Tinnitus Questionnaire (TQ) in one (Bakhshaee
2007). Four studies used different Likert scales as outcome mea-
surement (our secondary outcome measure) (Donaldson 1981;
Hulshof 1985; Hulshof 1986; Simpson 1999).
See:Characteristics of included studies; Characteristics of excluded
studies.
Risk of bias in included studies
Figure 1 and Figure 2 show the results of the risk of bias assessment
according to the Cochrane Collaboration’s tool for assessing risk
of bias. Figure 1 shows the judgements about each methodologi-
cal quality item presented as percentages across included studies,
whereas Figure 2 shows the judgement for each included study sep-
arately. Detailed information about the assessment can be found
in the Characteristics of included studies.
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Figure 1. ’Risk of bias’ graph: review authors’ judgements about each methodological quality item
presented as percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each methodological quality item for
each included study.
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Bakhshaee 2007 (gabapentin): this appears to be a cross-over trial
for which the randomisation procedure and treatment protocol are
not described clearly. It therefore scored low for sequence genera-
tion, allocation concealment and blinding. The drop-out rate was
high (59%) and these incomplete outcome data are not addressed.
Tinnitus patients with a sensorineural hearing loss of well-known
aetiology were excluded. This exclusion criterion is not described
sufficiently, but it is stated to include noise-induced hearing loss.
As this is one of the main causes of hearing loss, and consequently
tinnitus, this will decrease the generalisability of this study.
Donaldson 1981 (carbamazepine): this appears to be a single-blind
trial and therefore scored low for blinding. The drop-out rate is
high (21%) and these incomplete outcome data are not addressed.
The other items were not reported clearly in the paper.
Hulshof 1985 (carbamazepine): the drop-out rate in the interven-
tion group is high (41%) and these incomplete data are not ad-
dressed. The other items were not reported clearly in the paper.
Hulshof 1986 (flunarizine): due to incomplete reporting none of
the items to assess the risk of bias could be scored.
Piccirillo 2007 (gabapentin): all items were reported and method-
ologically sound (i.e. low risk of bias).
Simpson 1999 (lamotrigine): blinding appears to have been carried
out correctly as identical capsules were used for placebo. The other
items were not adequately reported and therefore could not be
assessed.
Witsell 2006 (gabapentin): the randomisation process, allocation
concealment and blinding are all reported and methodologically
sound (i.e. low risk of bias for these domains). The drop-out rate
was high (30%), however, and selective loss to follow up cannot
be precluded.
In summary, the overall risk of bias of the included studies is ’high’
or ’unclear’.
Effects of interventions
Improvement in tinnitus-specific health-related
quality of life
The studies included in this review did not show a positive effect
of anticonvulsants on the primary outcome. Only three studies, all
of gabapentin, evaluated the effect through a validated question-
naire (Bakhshaee 2007; Piccirillo 2007; Witsell 2006). One study
showed a negative effect of gabapentin, one study showed a small,
statistically non-significant, positive effect and the third study
showed no difference between gabapentin and placebo. When the
data of the first two studies are pooled (Witsell could not be in-
cluded because of lack of exact numbers) no effect of gabapentin
is found (standardised mean difference (SMD) 0.07, 95% confi-
dence interval (CI) -0.26 to 0.40).
Bakhshaee 2007 showed that treatment with gabapentin for four
weeks at 900 mg/d resulted in a negative effect of gabapentin com-
pared to placebo with an increase in Tinnitus Questionnaire (TQ)
score of 18.4 points (standardised mean difference (SMD) 0.82,
95% CI 0.07 to 1.58). This standard mean difference is low be-
cause of high standard deviations (20.22 and 23.36, with a total
possible score of 84). Piccirillo 2007 showed that treatment with
gabapentin for eight weeks at 900 to 3600 mg/d resulted in a pos-
itive, non-significant effect for gabapentin with a difference com-
pared to placebo of 2.4 points on the TinnitusHandicap Inventory
(THI) (SMD -0.11, 95%CI -0.48 to 0.25). The data in this study
also included high standard deviations (23.52 and 19.02, with a
total possible score of 100). In a subgroup of patients with normal
hearing the THI improved significantly more in the gabapentin
group than in the placebo group (difference 17.2 points, SMD
0.89, 95% CI -1.27 to -0.50). Witsell 2006 showed no differences
on the THI after a four-week treatment with gabapentin up to
1800 mg compared to placebo (exact numbers could not be ex-
tracted from the article).
Improvement in self-assessment of tinnitus severity
The patient’s self-assessment of their tinnitus, our secondary out-
come, was included in all studies as an outcome measurement.
Five out of six studies did not show a positive effect of anticonvul-
sants (Bakhshaee 2007; Donaldson 1981;Hulshof 1986; Piccirillo
2007; Simpson 1999; Witsell 2006). When these data are pooled
in a meta-analysis, however, this shows a small favourable effect of
anticonvulsants (risk difference (RD) 14%, 95% CI 6% to 22%).
This meta-analysis includes all levels of improvement on the vari-
ous Likert scale, and therefore these patients may still be annoyed
to some or a large degree by their tinnitus. It can be presumed
that the best possible scores on these Likert scales (complete effect,
abolition, not annoying, not annoying/disappeared, very much
better, much better) entail annulment of annoyance. Summarised
as near or total eradication of tinnitus annoyance, a meta-analysis
of these results showed no effect of anticonvulsants (RD 4%, 95%
CI -2% to 11%) (Bakhshaee 2007; Donaldson 1981; Hulshof
1985; Hulshof 1986; Piccirillo 2007; Simpson 1999). Figure 3
and Figure 4 show the results of these meta-analyses.
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Figure 3. Forest plot of comparison: 1 Self-assessment, outcome: 1.1 Any positive effect.
Figure 4. Forest plot of comparison: 1 Self-assessment, outcome: 1.2 near or total eradication of tinnitus
annoyance
Gabapentin
Bakhshaee 2007 showed no effect of gabapentin on a self-assess-
ment score (RD 5%, 95% CI -40% to 30%). Complete response
was achieved on this score in 13% in the gabapentin group and in
14% of the placebo group (RD 2%, 95% CI -26% to 23%).
Piccirillo 2007 reported a non-significant improvement in 19% in
the gabapentin group compared to 9% in the placebo group (RD
10%, 95% CI -2% to 22%) on a self-assessment score. A large
result was achieved in 2% in the gabapentin group and not in the
placebo group (RD 2%, 95% CI -3% to 6%). This difference is
also not significant.
Witsell 2006 found a significant effect for gabapentin using a
self-assessment score: 38% of patients in the gabapentin group
reported a positive effect compared to 7% of placebo patients (RD
30%, 95% CI 14% to 48%).
Carbamazepine
Donaldson 1981 showed that treatment with carbamazepine 200
mg twice a day for two months resulted in a non-significant posi-
tive effect in 45% as compared to 21% in the placebo group on a
self-assessment score (RD 10%, 95% CI -8% to 27%). A good or
excellent result was achieved in 38% in the carbamazepine group
and in 20%of the placebo group (RD18%, 95%CI -2% to 39%).
Hulshof 1985 showed that treatment with carbamazepine 150 mg
three times a day for 30 days resulted in a non-significant negative
effect: in 8% as compared to 13% in the placebo group on a self-
assessment score (RD -4%, 95% CI -21% to 13%).
Flunarizine
Hulshof 1986 showed that treatment with 10 mg flunarizine for
six weeks resulted in a non-significant improvement of tinnitus
in 44% as compared to 24% in the placebo group using a self-
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assessment score (RD 20%, 95% CI -6% to 46%). Disappearance
of the annoyance of tinnitus was non-significantly lower in the
flunarizine group; 16% in the flunarizine group compared to 20%
in the placebo group (RD -4%, 95% CI -25% to 17%)
Lamotrigine
Simpson 1999 showed that treatment with lamotrigine up to 100
mg for eight weeks resulted in a non-significant improvement in
tinnitus in 36% as compared to 19% in the placebo group using
a self-assessment score (RD 16%, 95% CI -6% to 38%). A large
improvement was found in 10% of the lamotrigine group and not
found in placebo group (RD 10%, 95% CI -2% to 21%). This
difference is also not significant.
Improvement in accompanying symptoms (e.g.
depression, anxiety or sleeping problems)
Only two studies included outcome measurements on accompa-
nying symptoms. Witsell et al did not find a significant differ-
ence in the total mood score of the Profile of Mood States (ex-
act numbers could not be extracted from the article) between the
gabapentin and the placebo group (Witsell 2006). Piccirillo et al
included the BeckDepression Scale and Brief Symptom Inventory
in their analysis, but did not include a description of these data in
their article (Piccirillo 2007).
Adverse drug effects
In all studies side effects were reported. Fifty-two of the 286
patients (18%) that received an anticonvulsant experienced side
effects. Nausea (12 patients) and dizziness (11 patients) were
the most frequently reported. Other side effects reported were:
headache (five patients), elevated tiredness (four patients), vom-
iting during the treatment (three patients), weight gain (two pa-
tients), sleep disturbance (two patients), and diarrhoea, mouth
sores and decreased libido (one patient). In 14 patients the side
effects were not specified.
D I S C U S S I O N
Summary of main results
This review of seven trials (453 patients) shows that current evi-
dence regarding the effectiveness of anticonvulsants has a signif-
icant risk of bias. Nevertheless, based on the findings in this re-
view anticonvulsants do not show a beneficial effect on tinnitus,
measured through validated questionnaires. The seven included
trials investigated four different anticonvulsants: gabapentin, car-
bamazepine, lamotrigine and flunarizine. Of the three studies
that measured improvement with a validated questionnaire (our
primary outcome), one study showed a significant negative (ad-
verse) effect of gabapentin compared to placebo with an increase
in Tinnitus Questionnaire (TQ) score of 18.4 points (standard-
ised mean difference (SMD) 0.82, 95% confidence interval (CI)
0.07 to 1.58). A second study did not show a significant effect
of gabapentin compared to placebo (difference 2.4 points on the
Tinnitus Handicap Inventory (THI), SMD -0.11, 95% CI -0.48
to 0.25). When the data from these two studies are pooled no
effect of gabapentin is found (SMD 0.07, 95% CI -0.26 to 0.40).
A third study comparing gabapentin and placebo did not show a
difference using the THI. A meta-analysis of ’any positive effect’
(yes versus no) based on a self-assessment score (secondary out-
come) showed a small beneficial effect (risk difference (RD) 14%,
95% CI 6% to 22%) for anticonvulsants. However, this effect
is not large enough to be considered clinically relevant. It shows
that in 14% an improvement can be seen, which is in itself a low
number. Secondly, in tinnitus a minor improvement is not always
enough to obtain the treatment goal: a decrease in annoyance to
a level in which it does not interfere with the patient’s quality of
life. The treatment goal to be aimed at is near or total eradication
of tinnitus annoyance: a meta-analysis of this outcome showed no
effect for anticonvulsants (RD 4%, 95% CI -2% to 11%). Side
effects of the anticonvulsants used were experienced by 18% of
patients.
Overall completeness and applicability of
evidence
The results of this review are only applicable to the general tinni-
tus population. Since tinnitus is a diverse symptom, different sub-
groups of tinnitus patients may exist, potentially leading to differ-
ent results for different therapies. Due to the lack of data on factors
that could potentially modify the effect of anticonvulsants (such
as degree of burden, aetiology of hearing loss, duration of tinnitus
or whether the patients actively seek help or not), it was not pos-
sible to perform subgroup analyses to identify patients that might
benefit from anticonvulsants. Piccirillo et al, however, showed a
beneficial effect of gabapentin in a subgroup with normal hearing
(Piccirillo 2007). It is thus possible that some subgroups might
benefit more than others from treatment with anticonvulsants.
Quality of the evidence
Most of the studies included in this review have amoderate or high
risk of bias as descriptions of the methodology used are minimal.
Potential biases in the review process
During the review process we identified potential biases both in
the individual trials and in the review process itself.
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Since tinnitus is a subjective symptom, no gold standard is avail-
able to measure the severity of the symptom. Furthermore, there
is as yet no consensus regarding the best way to measure treatment
effects, making it difficult to interpret and compare results. Vali-
dated tinnitus questionnaires are, however, deemed to be more re-
liable than other subjective measurements, such as visual analogue
scales and Likert scales. Audiometric measurements of tinnitus are
not regarded as reliable outcome parameters. We therefore used
validated questionnaires as our primary outcome measure. Of the
included studies one used the TQ and two the THI as outcome
measurement. These are the most commonly used questionnaires,
but as mentioned above it remains unclear whether these ques-
tionnaires are usable for measuring treatment effects (Kamalski
2010).
Due to the large variety of outcome measures used it was not
possible to explore publication bias in a funnel plot.
The authors of this review were not blinded to the authorship and
origin of the included studies since we knew most of the literature
before embarking on this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current evidence regarding the effectiveness of anticonvulsants in
patients with tinnitus has significant risk of bias. There is no evi-
dence from studies performed so far to show that the anticonvul-
sants studied (gabapentin, carbamazepine, flunarizine and lamot-
rigine) have a large positive effect in the treatment of tinnitus but
a small effect (of doubtful clinical significance) has been demon-
strated.
Implications for research
Future trials should be methodologically sound. They should be
set up as randomised clinical trials. Patients, treatment providers
and outcome assessors should be blinded. Randomisation should
be performed in a reliable way (e.g. by computer) and the placebo
used should be identical to the actual treatment. Results should
be analysed by intention-to-treat.
Consensus should be reached about evaluation methods so that
studies can be compared. A first step towards reaching this consen-
sus had been made by the Tinnitus Research Initiative (Langguth
2007). We would recommend following these guidelines on out-
comemeasurements. The two most commonly used validated tin-
nitus questionnaires are the Tinnitus Questionnaire (TQ) and the
Tinnitus Handicap Inventory (THI), so use of at least one of these
in evaluations is recommended.
Study populations should be clearly defined in future trials, in-
cluding degree of burden, aetiology of hearing loss, duration of
tinnitus and other tinnitus characteristics, and whether the pa-
tients actively seek help or not.
Future trials should have large enough study populations so that
possible effects in subgroups can be evaluated. Smaller trials should
only be performed in well-chosen subgroups. Decisions on the
type of subgroups should be based (if possible) on earlier studies
showing a possible (better) result in these subgroups.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bakhshaee 2007
Methods Prospective, double-blind, placebo-controlled, cross-over trial
Participants 30 participants with moderate to severe idiopathic subjective tinnitus
16 gabapentin, 14 placebo
Inclusion criteria:
• 36 to 81 years
• continuous non-pulsatile tinnitus
• duration at least 6 months
• total Tinnitus Questionnaire (TQ) score > 30
Exclusion criteria:
• active Ménière’s disease
• signs or symptoms of intracranial disease or vestibular disorder
• conductive hearing loss or surgically correctable component
• sensorineural hearing loss of well-known aetiology, such as noise-induced hearing
loss
• totally deaf or more than moderately severe loss (> 50) in at least one frequency
• concurrent treatment with centrally-acting medication
• diabetes mellitus
• related to gabapentin use (impaired renal function, (planned) pregnancy,
contraindications to gabapentin, metabolic or endocrine disorder)
• mental retardation and severe cognitive disorders
Interventions Intervention: 900 mg gabapentin per day
Control: identical placebo (opaque starch-filled gel capsules)
Duration: 4 weeks
Outcomes Primary outcome: psychoacoustically determined tinnitus loudness and TQ score
Secondary outcome: Tinnitus Severity Index score
Notes Drawbacks:
• Exclusion criteria result in an intervention group not representative of the
majority of tinnitus patients (patients with sensorineural hearing loss of well-known
aetiology such as noise-induced hearing loss are excluded)
Adverse events: 3% experienced dizziness
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “every participant received the same
treatment sequence, therefore evaluations
could be made with each participant serv-
ing as their own control”
Quote: “16 participants in the study group
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Bakhshaee 2007 (Continued)
and 14 in the control group completed the
protocol”
Comment: this study is described as a RCT
and the results show an intervention and a
placebo group. The methods section, how-
ever, describes every participant receiving
the same treatment sequence and serving
as their own control. This implies a cross-
over design
As it is stated clearly that everybody re-
ceived the same treatment sequence we be-
lieve that no randomisation was performed
Allocation concealment (selection bias) High risk Quote: “every participant received same
treatment sequence”
Comment: a fixed sequence excludes the
possibility of allocation concealment
Blinding (performance bias and detection
bias)
All groups
Unclear risk Quote: “double blind”
Quote: “neurontin capsules and placebo
were individually enclosed in snap-lock,
opaque starch-filled gel capsules by an in-
vestigational pharmacist”
Quote: “every participant received same
treatment sequence”
Comment: blinding not adequately de-
scribed
1) Identical pills suggests blinding of pa-
tients
2) Same treatment sequence makes blind-
ing of study personnel and outcome asses-
sors doubtful
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “42 patients were noncompliant
with the study instructions and one failed
to complete the study due to side effects”
Quote: “30 patients completed the proto-
col”
Comment: not adequately described; 59%
drop-out is implied (not included in the
analysis)
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Unclear risk • No adequate baseline table to check
comparability of groups
• Not described if groups were treated
equally
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Donaldson 1981
Methods Placebo-controlled, randomised, cross-over trial
Participants 78 tinnitus clinic patients
62 carbamazepine, 62 placebo (patients who dropped out not included)
Inclusion criteria:
• tinnitus
• sensorineural hearing loss
Exclusion criteria:
• conductive hearing loss
• deafness
Interventions Intervention: 100 mg carbamazepine twice a day
Control: placebo tablets
Duration: 2 times 2 months
Outcomes Patients’ assessment of tinnitus change on a percentage (not fully described, presumably
0% to 100%) analogue scale: excellent (abolition); good (> 60% reduction); partial (30%
to 60% reduction); no significant relief (< 30% reduction)
Notes Adverse events: types not described
18% withdrew because of side effects from carbamazepine and 3% withdrew because of
side effects from placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised system”
Comment: randomisation process not ex-
plained
Allocation concealment (selection bias) Unclear risk Comment: no information provided
Blinding (performance bias and detection
bias)
All groups
High risk Quote: “double blind system”
Comment: blinding is not explained. The
study date and the fact that no study phar-
macy is mentioned mean that adequate
blinding is judged highly unlikely
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “14 patients withdrew whilst tak-
ing carbamazepine and 2 whilst taking
placebo”
Comment: 21% drop-out (18% interven-
tion, 3% placebo) is too high and patients
that dropped out were excluded from anal-
yses
Selective reporting (reporting bias) Unclear risk No protocol available
19Anticonvulsants for tinnitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Donaldson 1981 (Continued)
Other bias Unclear risk • No adequate baseline table to check
comparability of groups
• Not described if groups were treated
equally
Hulshof 1985
Methods Double-blind, placebo-controlled, randomised trial
Participants 48 patients with annoying tinnitus
24 carbamazepine, 24 placebo
No further inclusion/exclusion criteria described
Interventions Intervention: 150 mg carbamazepine 3 times a day
Control: identical-looking gelatin placebo capsules
Duration: 30 days
Outcomes Likert scale (tinnitus disappeared, tinnitus improved, tinnitus did not disappear)
Notes Adverse events: 63% of carbamazepine patients experienced side effects (8 dizziness,
8 nausea, 4 headache, 2 tiredness, 2 vomiting, 1 diarrhoea). 4% of placebo patients
experienced side effects (1 headache)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised controlled trial”
Comment: randomisation process not ex-
plained
Allocation concealment (selection bias) Unclear risk Quote: “after randomisation”
Randomisation process not explained
Blinding (performance bias and detection
bias)
All groups
Unclear risk Quote: “double-blind controlled trial”
Quote: “identical-looking gelatin capsules”
Comment: blinding not adequately de-
scribed
• Identical pills suggest at least
blinding of patients
• Measurements of carbamazepine
levels in serum makes blinding of
personnel doubtful
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “10 patients withdrew in carba-
mazepine group because of side effects”
Comment: 42% drop-out in the interven-
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Hulshof 1985 (Continued)
tion group is very high; patients were in-
cluded in analyses
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Unclear risk • No adequate baseline table to check
comparability of groups
• Not described if groups were treated
equally
Hulshof 1986
Methods Double-blind, placebo-controlled, randomised clinical trial
Participants 50 patients with annoying tinnitus
25 flunarizine, 25 placebo
No further inclusion/exclusion criteria described
Interventions Intervention: 10 mg flunarizine once a day
Control: identical placebo capsules
Duration: 6 weeks
Outcomes Likert scale (0 tinnitus has disappeared, 1 tinnitus persists but is no longer annoying, 2
tinnitus annoying but less severe, 3 no change, 4 severity increased)
Notes Adverse events: 8% of flunarizine patients experienced sleepiness during the day. No side
effects were mentioned in the placebo group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomisation”
Comment: randomisation process not ex-
plained
Allocation concealment (selection bias) Unclear risk Quote: “randomisation”
Comment: randomisation process not ex-
plained
Blinding (performance bias and detection
bias)
All groups
Unclear risk Quote: “double blind”
Comment: blindingprocess not adequately
described
• Identical pills suggest at least
blinding of patients
• Measurement of flunarizine levels in
serum makes blinding of personnel
doubtful
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Hulshof 1986 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: not adequately described if
there were no drop-outs, or if the 50 pa-
tients analysed were the patients left over
after exclusion of a number of drop-outs
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Unclear risk • No adequate baseline table to check
comparability of groups
• Not described if groups were treated
equally
Piccirillo 2007
Methods Double-blind, placebo-controlled, randomised trial
Participants 135 subjects with severe idiopathic subjective tinnitus (1028 screened)
59 gabapentin, 56 placebo
Inclusion criteria:
• 18 to 65 years
• duration of 6 months or longer
• sufficient severity to disrupt daily activities
• Tinnitus Handicap Inventory (THI) > 38
Exclusion criteria:
• presence of a treatable otological disorder related to the tinnitus
• organic mental disorder
• related to gabapentin use (impaired renal function, previous use of gabapentin)
Interventions Intervention: 3600 mg gabapentin per day in 3 doses or highest possible dose reached
(titration: week 1, 900 mg/day; week 2, 1800 mg/day; week 3, 2700 mg/day; week 4,
3600 mg/day)
Control: identical blue placebo capsule, similar administration
Duration: 4 weeks titration period and 4-week fixed-dose period
Outcomes Primary outcome: change in THI from week 0 to 8 between treatment arms
Secondary outcomes: 1) Patient Global Impression of Change score, 2) Brief Symptom
Inventory, 3) Beck Depression Scale score
Notes Drawbacks:
• Some results difficult to interpret from tables because of different subgroups in
baseline and results tables
• Unclear why slightly more patients received gabapentin than placebo
Adverse events: 7% withdrew because of side effects (3 nausea, 2 weight gain, 2 sleep
disturbance, 2 dizziness, 1 seizure). It was not mentioned if the side effects occurred in
the gabapentin or the placebo group
Risk of bias
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Piccirillo 2007 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “sequentially randomised accord-
ing to a computer-generated random code”
Allocation concealment (selection bias) Low risk Quote: “research pharmacist maintained
the randomisation schedule”
Blinding (performance bias and detection
bias)
All groups
Low risk Quote: “double blind”
Quote: “matching placebo capsules”,
“identical blue capsules”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 16% drop out in gabapentin group and
14% in placebo group
Modified intention-to-treat analyses (in-
clusion of patients with at least 1 dose of
study medication and at least 1 follow-up
assessment)
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk -
Simpson 1999
Methods Double-blind, placebo-controlled, cross-over trial
Participants 33 subjects from a general tinnitus clinic population
No other inclusion criteria mentioned
Exclusion criteria
• younger than 18 or older than 75 years
• related to lamotrigine use (pregnancy, (history of ) treatment for epilepsy or
treatment with antiepileptic drugs, history of gastrointestinal hepatic or renal
insufficiency)
• < 5 on visual analogue scale (VAS) of 1 to 10 for “annoyance”
• tinnitus at present level for less than 6 months
Interventions Intervention: 100 mg/d lamotrigine (titration: week 1 to 2, 25 mg/day; week 3 to 4, 50
mg/day)
Control: matching placebo tablets
Duration: 4 weeks titration period, 4 weeks fixed-dose period, followed by same regimen
after cross-over
Outcomes Questionnaires (Likert: much better, better, no change, worse, much worse), visual ana-
logue scales (loudness, annoyance, awareness) and audiological measurements (pure tone
audiometry, masking audiogram, pitch matching of tinnitus, loudness matching of tin-
nitus, masking of tinnitus, residual inhibition and uncomfortable loudness levels) at 0
weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks
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Simpson 1999 (Continued)
Notes Drawbacks:
• No primary outcome measurement or time point stated
• No wash-out period
Adverse events: 3% of patients withdrew in the lamotrigine group (1 nausea, vomiting
and headache) and 3% of patients withdrew in the placebo group (1 dizziness and rash)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly allocated”
Comment: randomisation process not ex-
plained
Allocation concealment (selection bias) Unclear risk Randomisation process not explained
Blinding (performance bias and detection
bias)
All groups
Unclear risk Quote: “double-blind”
Quote: “matching placebo tablets”
Comment: blindingprocess not adequately
described. Identical pills suggest at least
blinding of patients
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6% drop-out, evenly distributed in placebo
and lamotrigine group
Left out from results
Selective reporting (reporting bias) Unclear risk No protocol available
No primary outcomemeasurement or time
point stated
Other bias Unclear risk • No adequate baseline table to check
comparability of groups
• Not described if groups were treated
equally
Witsell 2006
Methods Double-blind, placebo-controlled, randomised clinical trial
Participants 79 patients with moderate tinnitus (102 screened)
53 gabapentin, 26 placebo
Inclusion criteria:
• 18 to 70 years
• chief complaint of tinnitus > 3 months
• understands English and has a telephone
Exclusion criteria:
• related to gabapentin use (allergic to gabapentin, history of chronic renal failure,
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Witsell 2006 (Continued)
pancreatitis, hypotension, seizure disorder, past use of gabapentin, pregnant or breast
feeding)
• cognitive impairment
Interventions Intervention: 1800 mg gabapentin per day in 3 doses
Control: identical placebo capsules in same dosing schedule
Duration: 2 week escalating-dose period (week 1, 300 mg/day; week 2, 900 mg/day), 2
week fixed-dose period, 2 weeks descending-dose period (week 5, 900 mg/day; week 6,
300 mg/day)
Outcomes Primary outcome: Tinnitus Handicap Inventory (THI), no time period stated (ques-
tionnaire was administered at week 1, week 4, week 10)
Secondary outcome: Profile of Mood States (POMS)
Notes Adverse events: 2% of patients in the gabapentin group experienced side effects (1mouth
sores and decreased libido)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computerised random-number
generator”
Allocation concealment (selection bias) Low risk Quote: “key to randomisation was held by
the pharmacy”
Blinding (performance bias and detection
bias)
All groups
Low risk Quote: “placebo identical to the
gabapentin capsules”
Incomplete outcome data (attrition bias)
All outcomes
High risk 30% drop-out, selective loss to follow up
Unclear handling of drop-out
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Unclear risk • No adequate baseline table to check
comparability of groups
• Not described if groups were treated
equally
RCT: randomised controlled trial
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bauer 2006 ALLOCATION
Not randomised (cross-over trial with a set regiment)
Castagno 1989 Not available
Guth 1990 ALLOCATION
Random; randomisation process not explained
Cross-over design
PARTICIPANTS
66 patients (66 AOAA, 66 placebo)
Inclusion criteria:
• severe tinnitus
Exclusion criteria:
• women with child-bearing potential
• hepatic, cardiac, gastrointestinal or convulsive disorders
• mental incompetence
INTERVENTIONS
Intervention:
Amino-oxyacetic acid (AOAA) is not a registered anticonvulsant
Halmos 1982 Not available
Marks 1981 ALLOCATION
Not described
PARTICIPANTS
9 patients
Inclusion criteria:
• constant and unilateral tinnitus
• more than trivial tinnitus
• virtually normal hearing
• easily reproducible tinnitus matching
INTERVENTIONS
Intervention: single dose of 200 mg carbamazepine
Menkes 1998 ALLOCATION
Article is a letter to the editor and not a randomised controlled trial
Shulman 2008 ALLOCATION
Article is a comment and not a randomised controlled trial
Viada 1981 Not available
26Anticonvulsants for tinnitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Self-assessment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any positive effect 6 445 Risk Difference (M-H, Fixed, 95% CI) 0.14 [0.06, 0.22]
2 Near or total eradication of
tinnitus annoyance
6 379 Risk Difference (M-H, Fixed, 95% CI) 0.04 [-0.02, 0.11]
Comparison 2. Questionnaires
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Tinnitus Handicap Inventory
(THI)
1 115 Std. Mean Difference (IV, Fixed, 95% CI) -0.11 [-0.48, 0.25]
2 Tinnitus Questionnaire (TQ) 2 145 Std. Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.26, 0.40]
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Analysis 1.1. Comparison 1 Self-assessment, Outcome 1 Any positive effect.
Review: Anticonvulsants for tinnitus
Comparison: 1 Self-assessment
Outcome: 1 Any positive effect
Study or subgroup Experimental Control
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bakhshaee 2007 6/16 6/14 7.0 % -0.05 [ -0.40, 0.30 ]
Donaldson 1981 28/62 22/62 29.0 % 0.10 [ -0.08, 0.27 ]
Hulshof 1986 11/25 5/25 11.7 % 0.24 [ -0.01, 0.49 ]
Piccirillo 2007 11/59 5/57 27.1 % 0.10 [ -0.02, 0.22 ]
Simpson 1999 11/31 6/31 14.5 % 0.16 [ -0.06, 0.38 ]
Witsell 2006 18/48 1/15 10.7 % 0.31 [ 0.12, 0.49 ]
Total (95% CI) 241 204 100.0 % 0.14 [ 0.06, 0.22 ]
Total events: 85 (Experimental), 45 (Control)
Heterogeneity: Chi2 = 5.68, df = 5 (P = 0.34); I2 =12%
Test for overall effect: Z = 3.30 (P = 0.00095)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours placebo Favours anticonvulsant
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Analysis 1.2. Comparison 1 Self-assessment, Outcome 2 Near or total eradication of tinnitus annoyance.
Review: Anticonvulsants for tinnitus
Comparison: 1 Self-assessment
Outcome: 2 Near or total eradication of tinnitus annoyance
Study or subgroup Experimental Control
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bakhshaee 2007 2/16 2/14 7.9 % -0.02 [ -0.26, 0.23 ]
Donaldson 1981 13/34 8/40 19.4 % 0.18 [ -0.02, 0.39 ]
Hulshof 1985 2/24 3/24 12.7 % -0.04 [ -0.21, 0.13 ]
Hulshof 1986 4/25 5/25 13.2 % -0.04 [ -0.25, 0.17 ]
Piccirillo 2007 1/59 0/56 30.4 % 0.02 [ -0.03, 0.06 ]
Simpson 1999 3/31 0/31 16.4 % 0.10 [ -0.02, 0.21 ]
Total (95% CI) 189 190 100.0 % 0.04 [ -0.02, 0.11 ]
Total events: 25 (Experimental), 18 (Control)
Heterogeneity: Chi2 = 5.68, df = 5 (P = 0.34); I2 =12%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours placebo Favours anticonvulsant
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Analysis 2.1. Comparison 2 Questionnaires, Outcome 1 Tinnitus Handicap Inventory (THI).
Review: Anticonvulsants for tinnitus
Comparison: 2 Questionnaires
Outcome: 1 Tinnitus Handicap Inventory (THI)
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Piccirillo 2007 59 38.24 (23.52) 56 40.68 (19.02) 100.0 % -0.11 [ -0.48, 0.25 ]
Total (95% CI) 59 56 100.0 % -0.11 [ -0.48, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.55)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours anticonvulsant Favours placebo
Analysis 2.2. Comparison 2 Questionnaires, Outcome 2 Tinnitus Questionnaire (TQ).
Review: Anticonvulsants for tinnitus
Comparison: 2 Questionnaires
Outcome: 2 Tinnitus Questionnaire (TQ)
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bakhshaee 2007 16 65.16 (20.22) 14 46.75 (23.36) 19.2 % 0.82 [ 0.07, 1.58 ]
Piccirillo 2007 59 38.24 (23.52) 56 40.68 (19.02) 80.8 % -0.11 [ -0.48, 0.25 ]
Total (95% CI) 75 70 100.0 % 0.07 [ -0.26, 0.40 ]
Heterogeneity: Chi2 = 4.83, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours anticonvulsant Favours placebo
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A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL PubMed EMBASE (Ovid)
#1 MeSH descriptor Tinnitus explode all
trees
#2 tinnit*
#3 (#1 OR #2)
#4 MeSH descriptor Anticonvulsants ex-
plode all trees
#5 MeSH descriptor Carbamazepine
#6 MeSH descriptor Vigabatrin
#7 MeSH descriptor Phenobarbital
#8 MeSH descriptor Ethosuximide
#9 MeSH descriptor Clonazepam
#10 anticonvul* OR antiepilept* OR anti-
epilept*
#11 zonisamide OR AD 810 OR CI
912 OR zonegran OR carbamazepine OR
Finlepsin OR Neurotol OR Epitol OR
amizepine OR Tegretol OR vigabatrin OR
gamma Vinyl OR sabri
#12 oxcarbazepine OR GP 47680 OR
timox OR trileptal OR Phenobarbital
OR phenemal OR phenorbarbitone OR
Phenylbarbital OR phenylethylbarbituric
acid OR gardenal OR luminal OR meth-
suximide OR mesuximide
#13 N,2-dimethyl-2-phenylsuccinimide
OR celontinORpetinutinOR lamotrigine
OR lamictal OR lamiktal OR gabapentin
OR neurontin OR felbamate OR felbatol
OR taloxa OR W-554
#14 etiracetamOR levetiracetamORKep-
pra OR Emeside OR suksilep OR sux-
ilep OR zarontin OR clonazepam OR an-
telepsin OR rivotril OR Ro 5-4023 OR
clobazam OR frisium OR urbanyl
#15 #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11 OR #12 OR #13 OR
#14
#16 #3 AND #15
#1 Tinnitus [Mesh]
#2 tinnit* [tiab]
#3 #1 OR #2
#4 Anticonvulsants [Mesh]
#5 Carbamazepine [MeSH]
#6 Vigabatrin [MeSH]
#7 Phenobarbital [MeSH]
#8 Ethosuximide [MeSH]
#9 Clonazepam [MeSH]
#10 Clobazam [Substance Name]
#11 Etiracetam [Substance Name]
#12 Felbamate [Substance Name]
#13 Gabapentin [Substance Name]
#14 Lamotrigine [Substance Name]
#15 Methsuximide [Substance Name]
#16 Oxcarbazepine [Substance Name]
#17 Zonisamide [Substance Name]
#18 Anticonvulsants[Pharmacological Ac-
tion]
#
19 etiracetam[tiab] OR levetiracetam[tiab]
OR Keppra[tiab] OR Emeside[tiab] OR
suksilep[tiab] OR suxilep[tiab] OR zaron-
tin[tiab] OR clonazepam[tiab] OR an-
telepsin[tiab] OR rivotril[tiab] OR Ro 5-
4023[tiab] OR clobazam[tiab] OR fri-
sium[tiab] OR urbanyl [tiab]
#20 N,2-
dimethyl-2-phenylsuccinimide[tiab] OR
celontin[tiab] OR petinutin[tiab] OR lam-
otrigine[tiab]OR lamictal[tiab]OR lamik-
tal[tiab] OR gabapentin[tiab] OR neu-
rontin[tiab] OR felbamate[tiab] OR felba-
tol[tiab] OR taloxa[tiab] ORW-554
#21 oxcarbazepine[tiab]
OR GP 47680[tiab] OR timox[tiab] OR
trileptal[tiab] OR phenobarbital[tiab] OR
phenemal[tiab] OR phenorbarbitone[tiab]
OR phenylbarbital[tiab] OR phenylethyl-
barbituric acid[tiab]ORgardenal[tiab]OR
luminal[tiab] OR methsuximide[tiab] OR
mesuximide
#22 zonisamide[tiab] OR AD 810[tiab]
1. exp tinnitus/
2. tinnit*.tw.
3. 1 or 2
4. exp anticonvulsive agent/
5. exp anticonvulsant activity/
6. exp anticonvulsant therapy/
7. (anticonvul* OR antiepilept* OR anti-
epilept*).tw.
8. (zonisamideORAD810ORCI912OR
zonegranOR carbamazepine ORFinlepsin
OR Neurotol OR Epitol OR amizepine
OR Tegretol OR vigabatrin OR gamma
Vinyl OR sabri).tw.
9. (oxcarbazepineORGP47680ORtimox
OR trileptal OR Phenobarbital OR phen-
emal OR phenorbarbitone OR Phenylbar-
bital OR phenylethylbarbituric acid OR
gardenal OR luminal OR methsuximide
OR mesuximide).tw.
10. N,2-dimethyl-2-phenylsuccinimide
OR celontinORpetinutinOR lamotrigine
OR lamictal OR lamiktal OR gabapentin
OR neurontin OR felbamate OR felbatol
OR taloxa ORW-554).tw.
11. (etiracetamOR levetiracetamORKep-
pra OR Emeside OR suksilep OR sux-
ilep OR zarontin OR clonazepam OR an-
telepsin OR rivotril OR Ro 5-4023 OR
clobazam OR Frisium OR urbany).tw.
12. 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR
10 OR 11
13. 3 AND 12
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(Continued)
OR CI 912 [tiab] OR zonegran[tiab] OR
carbamazepine[tiab] OR finlepsin[tiab]
OR neurotol[tiab] OR epitol[tiab] OR
amizepine[tiab] OR tegretol[tiab] OR vi-
gabatrin[tiab] OR “gamma vinyl”[tiab]
OR sabri
#23 anticonvul*[tiab] OR
antiepilept*[tiab] OR anti-epilept* [tiab]
#24 #4OR #5 OR #6OR #7OR #8 OR #
9 OR #10 OR #11 OR #12 OR #13 OR #
14 OR #15 OR #16 OR #17 OR #18 OR
#19 OR #20 OR #21 OR #22 OR #23
#25 #3 AND #24
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